ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
ENGLEWOOD, CO / February 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the...
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
ENGLEWOOD, CO / February 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report...
Aytu BioPharma (AYTU) Fireside Chat
In this presentation, we welcome Aytu BioPharma, NASDAQ symbol AYTU, and with us today is their Chief Executive Officer, Josh Disbrow. Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. This Fireside Chat...
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
ENGLEWOOD, CO / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
ENGLEWOOD, CO / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced...
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT® as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR® for ADHD Patients
Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply DisruptionENGLEWOOD, CO / January 10, 2023 / Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them...
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a...
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT® Prescriptions Generated Since Inception of RxConnect
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply DisruptionAdzenys XR-ODT is the Only...
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
ENGLEWOOD, CO / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today...